Article

Genentech, Alcon named 'Best Companies' again

Fortune magazine has named Genentech and Alcon Laboratories to its latest '100 Best Companies to Work For' list of U.S. employers.

New York

-

Fortune

magazine has named Genentech and Alcon Laboratories to its latest “100 Best Companies to Work For” list of U.S. employers.

South San Francisco, CA-based Genentech, with almost 11,000 full-time employees, is seventh in the 2009 rankings. The achievement marks the company’s 11th consecutive year on the list, a distinction that cannot be claimed by any other biotechnology company, according to Genentech.

Fortune

noted that the company had instituted retention bonuses and severance ranging from 18 to 52 weeks’ pay for anyone whose employment is terminated after a merger.

This year marks Alcon Laboratories’ 11th consecutive time on the list, too. The company, which has about 7,200 employees in the United States, ranks 74th on the 2009 list.

Fortune

noted the company’s retirement program, in which every dollar contributed by an employee is matched with $2.40 from the company, and its “friendly” culture.

The magazine compiled the list based on the responses of more than 81,000 employees of 353 companies to a 57-question survey developed by the Great Place to Work Institute. Two-thirds of each company’s score was based on answers to the questionnaire, which was sent to at least 400 randomly selected employees of each company. The remaining one-third of a company’s score was based on responses to “culture audit” questions about the company’s demographics, pay, and benefits, as well as open-ended questions about philosophy, communication, and similar matters. Any company at least 7 years old and with more than 1,000 U.S. employees was eligible for inclusion.

The full list appears in the Feb. 2 issue of

Fortune

and also is available at

www.fortune.com/bestcompanies

.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.